PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16648567-5	2006	Moreover, administration of MONCPT (5-20 mg/kg) for 15 to 17 days significantly inhibited tumor growth in human androgen-independent prostate tumor (PC3) and human non-small cell lung tumor (A549) xenografts; the inhibition rates ranged from 29.6% to 98%.	10-methoxy-9-nitrocamptothecin	28-34	proprotein convertase subtilisin/kexin type 1	Homo sapiens	149-152	
16648567-6	2006	The cytotoxic effect of 1,000 nmol/L of MONCPT in PC3 cells was associated with causing an arrest in G0-G1 phase, whereas that of 10 and 100 nmol/L MONCPT was relative to a persistent block in G2-M phase.	10-methoxy-9-nitrocamptothecin	40-46	proprotein convertase subtilisin/kexin type 1	Homo sapiens	50-53	
16648567-7	2006	Furthermore, down-regulation of CDK2, CDK4, and cyclin D1 was observed in PC3 cells treated with 1,000 nmol/L of MONCPT, whereas overexpression of CDK7, CDK1, and cyclin B1 was seen in PC3 cells treated with 10 and 100 nmol/L of MONCPT.	10-methoxy-9-nitrocamptothecin	113-119	proprotein convertase subtilisin/kexin type 1	Homo sapiens	74-77	
16648567-7	2006	Furthermore, down-regulation of CDK2, CDK4, and cyclin D1 was observed in PC3 cells treated with 1,000 nmol/L of MONCPT, whereas overexpression of CDK7, CDK1, and cyclin B1 was seen in PC3 cells treated with 10 and 100 nmol/L of MONCPT.	10-methoxy-9-nitrocamptothecin	113-119	proprotein convertase subtilisin/kexin type 1	Homo sapiens	185-188